当前位置: X-MOL 学术Inflamm. Bowel Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease
Inflammatory Bowel Diseases ( IF 4.5 ) Pub Date : 2020-05-29 , DOI: 10.1093/ibd/izaa127
Mohamed Noureldin 1, 2, 3 , Shirley Cohen-Mekelburg 1, 3, 4 , Asadullah Mahmood 2 , Ryan Stidham 1, 3 , Peter D R Higgins 1 , Shail Govani 5 , Amar R Deshpande 6 , Akbar K Waljee 1, 4, 7
Affiliation  

5-aminosalicylate (5-ASA) medications have a long history of use for the treatment of inflammatory bowel disease and continue to be widely prescribed today. The effectiveness of 5-ASAs in ulcerative colitis is clear; however, studies have shown little benefit for induction or maintenance treatment of Crohn disease (CD). We aimed to quantify usage and examine trends in 5-ASA prescription rates in patients with CD.

中文翻译:


克罗恩病患者 5-氨基水杨酸盐​​药物使用趋势



5-氨基水杨酸盐​​ (5-ASA) 药物用于治疗炎症性肠病有着悠久的历史,并且至今仍被广泛使用。 5-ASA 对溃疡性结肠炎的疗效是明确的;然而,研究表明克罗恩病 (CD) 的诱导或维持治疗几乎没有什么益处。我们的目的是量化 CD 患者 5-ASA 处方率的使用情况并研究趋势。
更新日期:2020-05-29
down
wechat
bug